United States · Series D startup
5 rounds we have observed, with the 14 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$134Mraised across 5 rounds since 2010, from 5 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Venrock
Wellington Management
Perceptive Advisors
Deerfield
Cormorant Asset Management
Redmile Group
Casdin Capital
Tekla Capital ManagementFrom a historical funding recordSEC filing: $70M sold, first sale Jun 2015
From a historical funding recordSEC filing: $16M sold, first sale Dec 2014
Reported by bizjournals.comSEC filing: $13M sold, first sale Jul 2012
Reported by finsmes.comSEC filing: $2.7M sold, first sale Sept 2010
From a historical funding recordSEC filing: $2.5M sold, first sale Jun 2009
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Third Rock Ventures
Canaan
Roche Venture FundVenrockFidelityWellington ManagementPerceptive AdvisorsDeerfieldCormorant Asset ManagementRedmile GroupMissing a round, or an investor who was in one? Tell us.
CytomX Therapeutics's investors include Third Rock Ventures, Canaan, Roche Venture Fund, Venrock and Fidelity, and 9 more on record.
CytomX Therapeutics has raised $134M across 5 rounds since 2010.
CytomX Therapeutics's most recent round was a Series D of $70M in Jun 2015.
Its most recent round, $70M in Jun 2015, is also its largest on record.
CytomX Therapeutics's first round on record, in Mar 2010, was backed by Mike Panesis.
CytomX Therapeutics's latest named round is a Series D, in Jun 2015.
CytomX Therapeutics is based in the United States.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 